Filling an Unmet Need in MDS Treatment

Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).

While some agents have made progress in the treatment of MDS, stem cell transplant is still the only curative method, and patients need more options. But now that researchers have spent the last few years better understanding the biology of the disease, there are some promising trials and treatments in the pipeline, Komrokji says.